Elixirgen Scientific’s Quick-Muscle™ Skeletal – SeV Complete Kit (QMS-SeV) was used in a paper that was recently published in Molecular Therapy. Dr. Guangbin Xia (University of New Mexico)’s publication, “Therapeutic Genome Editing for Myotonic Dystrophy Type 1 Using CRISPR/Cas9” presents his results using CRISPR/Cas9 genome editing and induced pluripotent stem cell (iPSC) technology towards a potential therapeutic approach for Myotonic dystrophy type 1 (DM1).
Companies
About TEDCO
Off
Release date